Low dose Zebularine treatment enhances immunogenicity of tumor cells

Cancer Letters

Volumn 257, Issue 1, 2007, Pages 107-115

  Liu, Hua ^a   Xue, Zhong tian ^a   Sjögren, Hans Olov ^a   Salford, Leif G ^a   Widegren, Bengt ^a  

^a Department of Clinical Sciences ^*  (Sweden)

Author keywords

DNA methylation; IDO; Immunogenicity; Zebularine

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 10; N METHYLTRYPTOPHAN; ZEBULARINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL LINE; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA METHYLATION; DRUG MECHANISM; DRUG MEGADOSE; ENZYME SYNTHESIS; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO SELECTION; ISOGRAFT; LOW DRUG DOSE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTIDINE; CYTOKINES; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOSUPPRESSIVE AGENTS; MALE; NEOPLASMS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TRANSFECTION;

RATTUS;

EID: 34648820287     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.013     Document Type: Article

References (22)

1. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
2. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 4 (2005) 263-274
3. Wajed S.A., Laird P.W., and DeMeester T.R. DNA methylation: an alternative pathway to cancer. Ann. Surg. 234 (2001) 10-20
4. Jonathan C.C., Cindy B.M., Felicidad A.G., Ye W., Sheldon G., Victor E.M., Peter A.J., and Eric U.S. Inhibition of DNA methylation and reactivation of silenced genes by Zebularine. J. Natl. Cancer Inst. 95 (2003) 399-409
5. Jonathan C.C., Daniel J.W., Felicidad A.G., Gangning L., Xu G.L., Hu Y.G., Victor E.M., and Peter A.J. Continuous Zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. 24 (2004) 1270-1278
6. Jonathan C.C., Christine B.Y., Daniel J.W., Jody C., Chadra W., Gangning L., Victor E.M., Sheldon G., Torben F.O., Thomas T., and Peter A.J. Preferential response of cancer cells to Zebularine. Cancer Cell 6 (2004) 151-158
7. Liu G., Ying H., Zeng G., Wheeler C.J., Black K.L., and Yu J.S. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64 (2004) 4980-4986
8. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., and Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003) 1269-1274
9. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A., and Mellor A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114 (2004) 280-290
10. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4 (2004) 762-774
11. Munn D.H., and Mellor A.L. IDO and tolerance to tumor. Trends Mol. Med. 10 (2004) 15-18
12. Brodin N.T., Jansson B., Hedlund G., and Sjogren H.O. Use of a monoclonal rat anti-mouse Ig light chain (RAMOL-1) antibody reduces background binding in immunohistochemical and fluorescent antibody analysis. J. Histochem. Cytochem. 37 7 (1989) 1013-1024
13. Hegardt P., Widegren B., Li L., Sjogren B., Kjellman C., Sur I., and Sjogren H.O. Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol. Immunother. 50 9 (2001) 491-501
14. Visse E., Siesjö P., Widegren B., and Sjögren H.O. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with IFN-γ, IL-7 or B7-1 transfected tumor cells. Cancer Gene Ther. 6 1 (1999) 37-44
15. Robinson C.M., Shirey K.A., and Carlin J.M. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J. Interferon Cytokine Res. 23 8 (2003) 413-421
16. Chiaverotti T.A., Battula N., and Monnat Jr. R.J. Rat hypoxanthine phosphoribosyltransferase cDNA cloning and sequence analysis. Adv. Exp. Med. Biol. 309B (1991) 117-120
17. + T regulatory cell activities in lung cancer. Cancer Res. 65 (2005) 5211-5220
18. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., and Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin 1, potentiates cancer chemotherapy. Nat. Med. 11 (2005) 312-319
19. Feinberg A.P., Ohlsson R., and Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7 1 (2006) 21-33
20. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., Bayar E., Lyons J., Rosenfeld C.S., Cortes J., and Kantarjian H.M. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2V-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
21. Issa J.P., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., Talpaz M., Garcia-Manero G., and Kantarjian H.M. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23 (2005) 3948-3956
22. Stresemann C., Brueckner B., Musch T., Stopper H., and Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66 5 (2006) 2794-2800